---
reference_id: "PMID:38710875"
title: Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mTOR-related epilepsy.
authors:
- Ribierre T
- Bacq A
- Donneger F
- Doladilhe M
- Maletic M
- Roussel D
- Le Roux I
- Chassoux F
- Devaux B
- Adle-Biassette H
- Ferrand-Sorbets S
- Dorfmüller G
- Chipaux M
- Baldassari S
- Poncer JC
- Baulac S
journal: Nat Neurosci
year: '2024'
doi: 10.1038/s41593-024-01634-2
content_type: abstract_only
---

# Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mTOR-related epilepsy.
**Authors:** Ribierre T, Bacq A, Donneger F, Doladilhe M, Maletic M, Roussel D, Le Roux I, Chassoux F, Devaux B, Adle-Biassette H, Ferrand-Sorbets S, Dorfmüller G, Chipaux M, Baldassari S, Poncer JC, Baulac S
**Journal:** Nat Neurosci (2024)
**DOI:** [10.1038/s41593-024-01634-2](https://doi.org/10.1038/s41593-024-01634-2)

## Content

1. Nat Neurosci. 2024 Jun;27(6):1125-1136. doi: 10.1038/s41593-024-01634-2. Epub 
2024 May 6.

Targeting pathological cells with senolytic drugs reduces seizures in 
neurodevelopmental mTOR-related epilepsy.

Ribierre T(1)(2)(3), Bacq A(1), Donneger F(4), Doladilhe M(1), Maletic M(1), 
Roussel D(1), Le Roux I(1), Chassoux F(5)(6), Devaux B(5)(6), Adle-Biassette 
H(7), Ferrand-Sorbets S(8), Dorfmüller G(8), Chipaux M(8), Baldassari S(1), 
Poncer JC(4), Baulac S(9).

Author information:
(1)Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, 
Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.
(2)Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland.
(3)NeuroNA Human Cellular Neuroscience Platform, Fondation Campus Biotech 
Geneva, Geneva, Switzerland.
(4)Institut du Fer à Moulin, INSERM, Sorbonne Université, UMR-S 1270, Paris, 
France.
(5)Service de Neurochirurgie, AP-HP, Hôpital Lariboisière, Paris, France.
(6)GHU Paris, Psychiatrie et Neurosciences, Paris, France.
(7)Université de Paris Cité, Service d'Anatomie Pathologique, AP-HP, Hôpital 
Lariboisière, DMU DREAM, UMR 1141, INSERM, Paris, France.
(8)Department of Pediatric Neurosurgery, Rothschild Foundation Hospital, Paris, 
France.
(9)Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, 
Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France. 
stephanie.baulac@icm-institute.org.

Comment in
    Nat Rev Drug Discov. 2024 Jul;23(7):499. doi: 10.1038/d41573-024-00092-6.

Cortical malformations such as focal cortical dysplasia type II (FCDII) are 
associated with pediatric drug-resistant epilepsy that necessitates 
neurosurgery. FCDII results from somatic mosaicism due to post-zygotic mutations 
in genes of the PI3K-AKT-mTOR pathway, which produce a subset of dysmorphic 
cells clustered within healthy brain tissue. Here we show a correlation between 
epileptiform activity in acute cortical slices obtained from human surgical 
FCDII brain tissues and the density of dysmorphic neurons. We uncovered multiple 
signatures of cellular senescence in these pathological cells, including p53/p16 
expression, SASP expression and senescence-associated β-galactosidase activity. 
We also show that administration of senolytic drugs (dasatinib/quercetin) 
decreases the load of senescent cells and reduces seizure frequency in an 
MtorS2215F FCDII preclinical mouse model, providing proof of concept that 
senotherapy may be a useful approach to control seizures. These findings pave 
the way for therapeutic strategies selectively targeting mutated senescent cells 
in FCDII brain tissue.

© 2024. The Author(s).

DOI: 10.1038/s41593-024-01634-2
PMCID: PMC11156583
PMID: 38710875 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no competing interests.